Skip to content

Omeros OMER Total Current Liabilities

Total Current Liabilities at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$35.15M+28.5%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$57.71M-18.6%
Immunome logo
ImmunomeIMNM
$27.41M-11.0%
Vor Biopharma logo
Vor BiopharmaVOR
$16.08M-3.9%
Annexon logo
AnnexonANNX
$35.94M+7.1%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$209M+8.9%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$775.86M+313%
P/S8.6×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:LiabilitiesCurrent.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's total current liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's total current liabilities?
Omeros (OMER) reported total current liabilities of $59.44M in Q1 2026.
How has Omeros's total current liabilities changed year-over-year?
Omeros's total current liabilities decreased by 28.6% year-over-year, from $83.22M to $59.44M.
What is the long-term trend for Omeros's total current liabilities?
Over 5 years (2020 to 2025), Omeros's total current liabilities has grown at a 16.3% compound annual growth rate (CAGR), from $36.74M to $78.06M.
What does total current liabilities mean?
The sum of all obligations due within one year — payables, accrued expenses, current debt, deferred revenue, and other short-term liabilities.